Hvsen Biotechnology Co., Ltd.

SZSE:300871 Stock Report

Market Cap: CN¥1.9b

Hvsen Biotechnology Valuation

Is 300871 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300871 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300871 (CN¥11.01) is trading below our estimate of fair value (CN¥89.16)

Significantly Below Fair Value: 300871 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300871?

Key metric: As 300871 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300871. This is calculated by dividing 300871's market cap by their current revenue.
What is 300871's PS Ratio?
PS Ratio1.6x
SalesCN¥1.12b
Market CapCN¥1.92b

Price to Sales Ratio vs Peers

How does 300871's PS Ratio compare to its peers?

The above table shows the PS ratio for 300871 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.3x
301065 Zhejiang Benli Technology
2.9xn/aCN¥2.0b
000590 Tus-Pharmaceutical Group
6.4xn/aCN¥2.2b
002370 Zhejiang Yatai Pharmaceutical
4.9xn/aCN¥2.1b
002826 Tibet AIM Pharm
3.2xn/aCN¥2.0b
300871 Hvsen Biotechnology
1.6x20.0%CN¥1.8b

Price-To-Sales vs Peers: 300871 is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does 300871's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.28b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$758.59m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$399.55m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
300871 1.6xIndustry Avg. 3.7xNo. of Companies36PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 300871 is good value based on its Price-To-Sales Ratio (1.6x) compared to the CN Pharmaceuticals industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 300871's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300871 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: 300871 is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

7D

-2.1%

1Y

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

7D

-1.7%

1Y

16.8%